Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Luger

Showing results (241-250 of 311) with videos related to

Pageof 32
Sort By:
Blood Advances|February 18, 2026
CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?Flavia Gava, Bonnie Yates, Zhouxin Sun, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Clinical Transplantation|September 9, 2005
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorderDonald E Tsai, Nicole A Aqui, John E Tomaszewski, et al.
The New England Journal of Medicine|July 13, 2012
Blockade of lymphocyte chemotaxis in visceral graft-versus-host diseaseRan Reshef, Selina M Luger, Elizabeth O Hexner, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Leukemia Research|November 4, 2022
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profilingChezi Ganzel, Zhuoxin Sun, Timour Baslan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2018
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant RecipientsAlex Ganetsky, Jennifer H Han, Mitchell E Hughes, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Blood|January 13, 2016
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.
Pageof 32

Showing results (241-250 of 311) with videos related to

Sort By:
Pageof 32
Blood Advances|February 18, 2026
CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?Flavia Gava, Bonnie Yates, Zhouxin Sun, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Clinical Transplantation|September 9, 2005
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorderDonald E Tsai, Nicole A Aqui, John E Tomaszewski, et al.
The New England Journal of Medicine|July 13, 2012
Blockade of lymphocyte chemotaxis in visceral graft-versus-host diseaseRan Reshef, Selina M Luger, Elizabeth O Hexner, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Leukemia Research|November 4, 2022
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profilingChezi Ganzel, Zhuoxin Sun, Timour Baslan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2018
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant RecipientsAlex Ganetsky, Jennifer H Han, Mitchell E Hughes, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Blood|January 13, 2016
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.
Pageof 32